UNITED STATES | ||||
SECURITIES AND EXCHANGE COMMISSION | ||||
Washington, D.C. 20549 | ||||
FORM 10-Q | ||||
(Mark One) | ||||
Q | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||
For the quarterly period ended September 30, 2013 | ||||
OR | ||||
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||
For the transition period from ________________ to ______________ | ||||
Commission File Number: 001-14273 | ||||
CORE LABORATORIES N.V. | ||||
(Exact name of registrant as specified in its charter) | ||||
The Netherlands | Not Applicable | |||
(State of other jurisdiction of | (I.R.S. Employer Identification No.) | |||
incorporation or organization) | ||||
Strawinskylaan 913 | ||||
Tower A, Level 9 | ||||
1077 XX Amsterdam | ||||
The Netherlands | Not Applicable | |||
(Address of principal executive offices) | (Zip Code) | |||
(31-20) 420-3191 | ||||
(Registrant's telephone number, including area code) | ||||
None | ||||
(Former name, former address and former fiscal year, if changed since last report) |
Large accelerated filer Q | Accelerated filer o | Non-accelerated filer o | Smaller reporting company o |
(Do not check if a smaller reporting company) |
CORE LABORATORIES N.V. | ||
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2013 | ||
INDEX | ||
PART I - FINANCIAL INFORMATION | ||
Page | ||
Item 1. | Financial Statements | |
PART II - OTHER INFORMATION | ||
September 30, 2013 | December 31, 2012 | ||||||
ASSETS | (Unaudited) | ||||||
CURRENT ASSETS: | |||||||
Cash and cash equivalents | $ | 22,204 | $ | 19,226 | |||
Accounts receivable, net of allowance for doubtful accounts of $3,286 and $3,516 at 2013 and 2012, respectively | 205,121 | 184,774 | |||||
Inventories | 53,646 | 49,265 | |||||
Prepaid expenses | 13,305 | 14,959 | |||||
Income tax receivable | 4,359 | 17,943 | |||||
Other current assets | 9,193 | 10,740 | |||||
TOTAL CURRENT ASSETS | 307,828 | 296,907 | |||||
PROPERTY, PLANT AND EQUIPMENT, net | 135,001 | 125,418 | |||||
INTANGIBLES, net | 10,836 | 8,721 | |||||
GOODWILL | 163,337 | 163,337 | |||||
DEFERRED TAX ASSETS, net | 5,866 | 13,224 | |||||
OTHER ASSETS | 34,608 | 28,909 | |||||
TOTAL ASSETS | $ | 657,476 | $ | 636,516 | |||
LIABILITIES AND EQUITY | |||||||
CURRENT LIABILITIES: | |||||||
Accounts payable | $ | 53,901 | $ | 55,168 | |||
Accrued payroll and related costs | 35,318 | 34,919 | |||||
Taxes other than payroll and income | 10,338 | 11,787 | |||||
Unearned revenue | 12,507 | 13,868 | |||||
Income tax payable | 10,361 | 9,542 | |||||
Other accrued expenses | 15,405 | 15,226 | |||||
TOTAL CURRENT LIABILITIES | 137,830 | 140,510 | |||||
LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS | 256,007 | 234,033 | |||||
DEFERRED COMPENSATION | 34,645 | 28,112 | |||||
DEFERRED TAX LIABILITIES, net | 5,273 | 6,777 | |||||
OTHER LONG-TERM LIABILITIES | 39,430 | 39,171 | |||||
COMMITMENTS AND CONTINGENCIES (Note 6) | |||||||
EQUITY: | |||||||
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding | — | — | |||||
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 46,750,002 issued and 45,366,384 outstanding at 2013 and 47,899,584 issued and 46,349,411 outstanding at 2012 | 1,203 | 1,233 | |||||
Additional paid-in capital | — | — | |||||
Retained earnings | 370,905 | 361,255 | |||||
Accumulated other comprehensive income (loss) | (8,108 | ) | (8,413 | ) | |||
Treasury shares (at cost), 1,383,618 at 2013 and 1,550,173 at 2012 | (185,783 | ) | (171,845 | ) | |||
Total Core Laboratories N.V. shareholders' equity | 178,217 | 182,230 | |||||
Non-controlling interests | 6,074 | 5,683 | |||||
TOTAL EQUITY | 184,291 | 187,913 | |||||
TOTAL LIABILITIES AND EQUITY | $ | 657,476 | $ | 636,516 |
Three Months Ended | |||||||
September 30, | |||||||
2013 | 2012 | ||||||
(Unaudited) | |||||||
REVENUE: | |||||||
Services | $ | 194,267 | $ | 174,465 | |||
Product sales | 78,896 | 70,963 | |||||
Total revenue | 273,163 | 245,428 | |||||
OPERATING EXPENSES: | |||||||
Cost of services, exclusive of depreciation expense shown below | 110,087 | 102,935 | |||||
Cost of product sales, exclusive of depreciation expense shown below | 57,340 | 52,406 | |||||
General and administrative expenses, exclusive of depreciation expense shown below | 14,346 | 10,504 | |||||
Depreciation | 6,396 | 6,170 | |||||
Amortization | 357 | 289 | |||||
Other (income) expense, net | 41 | (2,256 | ) | ||||
OPERATING INCOME | 84,596 | 75,380 | |||||
Interest expense | 2,302 | 2,160 | |||||
Income before income tax expense | 82,294 | 73,220 | |||||
Income tax expense | 20,490 | 18,671 | |||||
Net income | 61,804 | 54,549 | |||||
Net income (loss) attributable to non-controlling interests | (91 | ) | 146 | ||||
Net income attributable to Core Laboratories N.V. | $ | 61,895 | $ | 54,403 | |||
EARNINGS PER SHARE INFORMATION: | |||||||
Basic earnings per share attributable to Core Laboratories N.V. | $ | 1.36 | $ | 1.15 | |||
Diluted earnings per share attributable to Core Laboratories N.V. | $ | 1.35 | $ | 1.14 | |||
Cash dividends per share | $ | 0.32 | $ | 0.28 | |||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | |||||||
Basic | 45,526 | 47,232 | |||||
Diluted | 45,828 | 47,528 |
Nine Months Ended | |||||||
September 30, | |||||||
2013 | 2012 | ||||||
(Unaudited) | |||||||
REVENUE: | |||||||
Services | $ | 564,424 | $ | 512,883 | |||
Product sales | 232,805 | 213,742 | |||||
Total revenue | 797,229 | 726,625 | |||||
OPERATING EXPENSES: | |||||||
Cost of services, exclusive of depreciation expense shown below | 329,901 | 304,871 | |||||
Cost of product sales, exclusive of depreciation expense shown below | 164,674 | 155,990 | |||||
General and administrative expenses, exclusive of depreciation expense shown below | 38,328 | 30,883 | |||||
Depreciation | 17,775 | 16,554 | |||||
Amortization | 967 | 865 | |||||
Other (income) expense, net | 82 | (3,950 | ) | ||||
OPERATING INCOME | 245,502 | 221,412 | |||||
Interest expense | 6,834 | 6,528 | |||||
Income before income tax expense | 238,668 | 214,884 | |||||
Income tax expense | 60,190 | 53,454 | |||||
Net income | 178,478 | 161,430 | |||||
Net income (loss) attributable to non-controlling interests | 391 | 160 | |||||
Net income attributable to Core Laboratories N.V. | $ | 178,087 | $ | 161,270 | |||
EARNINGS PER SHARE INFORMATION: | |||||||
Basic earnings per share attributable to Core Laboratories N.V. | $ | 3.88 | $ | 3.40 | |||
Diluted earnings per share attributable to Core Laboratories N.V. | $ | 3.86 | $ | 3.38 | |||
Cash dividends per share | $ | 0.96 | $ | 0.84 | |||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | |||||||
Basic | 45,854 | 47,436 | |||||
Diluted | 46,150 | 47,754 |
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||
(Unaudited) | (Unaudited) | ||||||||||||||
Net income | $ | 61,804 | $ | 54,549 | $ | 178,478 | $ | 161,430 | |||||||
Pension and other postretirement benefit plans | |||||||||||||||
Prior service cost | |||||||||||||||
Amortization to net income of transition asset | (21 | ) | (21 | ) | (65 | ) | (65 | ) | |||||||
Amortization to net income of prior service cost | 39 | 39 | 119 | 119 | |||||||||||
Amortization to net income of actuarial loss | 117 | — | 351 | — | |||||||||||
Income taxes on pension and other postretirement benefit plans | (33 | ) | (5 | ) | (101 | ) | (14 | ) | |||||||
Comprehensive income | 61,906 | 54,562 | 178,782 | 161,470 | |||||||||||
Comprehensive income (loss) attributable to non-controlling interests | (91 | ) | 146 | 391 | 160 | ||||||||||
Comprehensive income attributable to Core Laboratories N.V. | $ | 61,997 | $ | 54,416 | $ | 178,391 | $ | 161,310 |
Nine Months Ended | |||||||
September 30, | |||||||
2013 | 2012 | ||||||
(Unaudited) | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
Net income | $ | 178,478 | $ | 161,430 | |||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Stock-based compensation | 15,408 | 13,503 | |||||
Depreciation and amortization | 18,742 | 17,419 | |||||
(Gain) on insurance recovery | — | (101 | ) | ||||
(Increase) decrease in value of life insurance policies | (3,194 | ) | (1,659 | ) | |||
Deferred income taxes | 6,212 | (811 | ) | ||||
Other non-cash items | 676 | 484 | |||||
Changes in assets and liabilities: | |||||||
Accounts receivable | (20,425 | ) | (12,395 | ) | |||
Inventories | (5,143 | ) | (896 | ) | |||
Prepaid expenses and other current assets | 14,595 | (8,916 | ) | ||||
Other assets | (414 | ) | 51 | ||||
Accounts payable | (1,506 | ) | (11,975 | ) | |||
Accrued expenses | 1,788 | (3,284 | ) | ||||
Unearned revenue | (1,361 | ) | (6,321 | ) | |||
Other long-term liabilities | 6,792 | 5,621 | |||||
Net cash provided by operating activities | 210,648 | 152,150 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
Capital expenditures | (26,988 | ) | (24,154 | ) | |||
Patents and other intangibles | (3,083 | ) | (1,096 | ) | |||
Cash settled for acquisition | — | 1,632 | |||||
Investment in non-consolidated affiliates | (50 | ) | — | ||||
Proceeds from sale of assets | 852 | 499 | |||||
Proceeds from insurance recovery | — | 101 | |||||
Premiums on life insurance | (2,553 | ) | (1,727 | ) | |||
Net cash used in investing activities | (31,822 | ) | (24,745 | ) | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
Repayment of debt | (51,035 | ) | (53,330 | ) | |||
Proceeds from debt | 73,000 | 41,000 | |||||
Stock options exercised | 83 | 5 | |||||
Excess tax benefits from stock-based compensation | 2,500 | 3,479 | |||||
Debt financing costs | — | (7 | ) | ||||
Dividends paid | (44,125 | ) | (39,876 | ) | |||
Repurchase of common shares | (156,271 | ) | (83,350 | ) | |||
Net cash used in financing activities | (175,848 | ) | (132,079 | ) | |||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 2,978 | (4,674 | ) | ||||
CASH AND CASH EQUIVALENTS, beginning of period | 19,226 | 29,332 | |||||
CASH AND CASH EQUIVALENTS, end of period | $ | 22,204 | $ | 24,658 |
September 30, 2013 | December 31, 2012 | ||||||
(Unaudited) | |||||||
Finished goods | $ | 40,218 | $ | 38,572 | |||
Parts and materials | 10,312 | 8,818 | |||||
Work in progress | 3,116 | 1,875 | |||||
Total inventories | $ | 53,646 | $ | 49,265 |
September 30, 2013 | December 31, 2012 | ||||||
(Unaudited) | |||||||
Senior notes | $ | 150,000 | $ | 150,000 | |||
Credit facility | 106,000 | 84,000 | |||||
Capital lease obligations | 39 | 73 | |||||
Total debt | 256,039 | 234,073 | |||||
Less - current maturities of long-term debt and capital lease obligations | 32 | 40 | |||||
Long-term debt and capital lease obligations, net | $ | 256,007 | $ | 234,033 |
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||
(Unaudited) | (Unaudited) | ||||||||||||||
Service cost | $ | 394 | $ | 273 | $ | 1,178 | $ | 845 | |||||||
Interest cost | 417 | 409 | 1,248 | 1,262 | |||||||||||
Expected return on plan assets | (321 | ) | (292 | ) | (961 | ) | (902 | ) | |||||||
Amortization of transition asset | (21 | ) | (21 | ) | (65 | ) | (65 | ) | |||||||
Amortization of prior service cost | 39 | 39 | 119 | 119 | |||||||||||
Amortization of actuarial loss | 117 | — | 351 | — | |||||||||||
Net periodic pension cost | $ | 625 | $ | 408 | $ | 1,870 | $ | 1,259 |
(Unaudited) | Fair Value Measurement at | ||||||||||||||
September 30, 2013 | |||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||
Assets: | |||||||||||||||
Deferred compensation trust assets (1) | $ | 16,043 | $ | — | $ | 16,043 | $ | — | |||||||
Liabilities: | |||||||||||||||
Deferred compensation plan | $ | 23,270 | $ | 1,791 | $ | 21,479 | $ | — |
Fair Value Measurement at | |||||||||||||||
December 31, 2012 | |||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||
Assets: | |||||||||||||||
Deferred compensation trust assets (1) | $ | 12,654 | $ | — | $ | 12,654 | $ | — | |||||||
Liabilities: | |||||||||||||||
Deferred compensation plan | $ | 18,579 | $ | 2,667 | $ | 15,912 | $ | — | |||||||
(1) Trust assets consist of the cash surrender value of life insurance policies and are intended to assist in the funding of the deferred compensation plan. |
(Unaudited) | Common Shares | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Treasury Stock | Non-Controlling Interests | Total Equity | ||||||||||||||||||||
December 31, 2012 | $ | 1,233 | $ | — | $ | 361,255 | $ | (8,413 | ) | $ | (171,845 | ) | $ | 5,683 | $ | 187,913 | |||||||||||
Stock options exercised | — | (1,411 | ) | — | — | 1,494 | — | 83 | |||||||||||||||||||
Stock based-awards | — | 2,291 | (327 | ) | — | 13,444 | — | 15,408 | |||||||||||||||||||
Tax benefit of stock-based awards issued | — | 2,500 | — | — | — | — | 2,500 | ||||||||||||||||||||
Repurchase of common shares | — | — | — | — | (156,271 | ) | — | (156,271 | ) | ||||||||||||||||||
Dividends paid | — | — | (44,125 | ) | — | — | — | (44,125 | ) | ||||||||||||||||||
Cancellation of common shares | (30 | ) | (3,380 | ) | (123,985 | ) | — | 127,395 | — | — | |||||||||||||||||
Amortization of deferred pension costs, net of tax | — | — | — | 305 | — | — | 305 | ||||||||||||||||||||
Net income (loss) | — | — | 178,087 | — | — | 391 | 178,478 | ||||||||||||||||||||
September 30, 2013 | $ | 1,203 | $ | — | $ | 370,905 | $ | (8,108 | ) | $ | (185,783 | ) | $ | 6,074 | $ | 184,291 |
September 30, 2013 | December 31, 2012 | ||||||
(Unaudited) | |||||||
Prior service cost | $ | (526 | ) | $ | (616 | ) | |
Transition asset | 146 | 195 | |||||
Unrecognized net actuarial loss | (7,728 | ) | (7,992 | ) | |||
Total accumulated other comprehensive income (loss) | $ | (8,108 | ) | $ | (8,413 | ) |
Three Months Ended | Nine Months Ended | ||||||||||
September 30, | September 30, | ||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||
(Unaudited) | (Unaudited) | ||||||||||
Weighted average basic common shares outstanding | 45,526 | 47,232 | 45,854 | 47,436 | |||||||
Effect of dilutive securities: | |||||||||||
Stock options | — | 11 | 1 | 12 | |||||||
Performance shares | 135 | 136 | 115 | 128 | |||||||
Restricted stock | 167 | 149 | 180 | 178 | |||||||
Weighted average diluted common and potential common shares outstanding | 45,828 | 47,528 | 46,150 | 47,754 |
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||
(Unaudited) | (Unaudited) | ||||||||||||||
Sale of assets | $ | (155 | ) | $ | (70 | ) | $ | (687 | ) | $ | (383 | ) | |||
Results of non-consolidated subsidiaries | 43 | (234 | ) | (142 | ) | (481 | ) | ||||||||
Foreign exchange | 518 | (610 | ) | 3,040 | (280 | ) | |||||||||
Rents and royalties | (156 | ) | (214 | ) | (599 | ) | (809 | ) | |||||||
Insurance recovery | (336 | ) | (1,023 | ) | (882 | ) | (4,490 | ) | |||||||
Legal entity realignment | — | — | — | 1,860 | |||||||||||
NYSE Euronext Amsterdam listing | — | — | — | 923 | |||||||||||
Other, net | 127 | (105 | ) | (648 | ) | (290 | ) | ||||||||
Total other (income) expense, net | $ | 41 | $ | (2,256 | ) | $ | 82 | $ | (3,950 | ) |
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||
(Unaudited) | (Unaudited) | ||||||||||||||
Australian Dollar | $ | 182 | $ | 47 | $ | 391 | $ | 32 | |||||||
British Pound | (430 | ) | (127 | ) | 111 | (68 | ) | ||||||||
Canadian Dollar | (278 | ) | (581 | ) | 690 | (599 | ) | ||||||||
Euro | 266 | (59 | ) | 620 | (66 | ) | |||||||||
Indonesian Rupiah | 320 | 18 | 373 | 158 | |||||||||||
Malaysian Ringgit | 144 | (33 | ) | 332 | 46 | ||||||||||
Mexican Peso | 52 | (179 | ) | 116 | (140 | ) | |||||||||
Russian Ruble | 16 | 164 | (38 | ) | 108 | ||||||||||
Other currencies, net | 246 | 140 | 445 | 249 | |||||||||||
Total (gain) loss | $ | 518 | $ | (610 | ) | $ | 3,040 | $ | (280 | ) |
• | Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. |
• | Production Enhancement: Includes services and products relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects. |
• | Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs. |
(Unaudited) | Reservoir Description | Production Enhancement | Reservoir Management | Corporate & Other 1 | Consolidated | ||||||||||||||
Three Months Ended September 30, 2013 | |||||||||||||||||||
Revenues from unaffiliated customers | $ | 131,533 | $ | 119,511 | $ | 22,119 | $ | — | $ | 273,163 | |||||||||
Inter-segment revenues | 656 | 791 | 301 | (1,748 | ) | — | |||||||||||||
Segment operating income (loss) | 35,938 | 42,284 | 6,516 | (142 | ) | 84,596 | |||||||||||||
Total assets (at end of period) | 320,505 | 261,970 | 37,005 | 37,996 | 657,476 | ||||||||||||||
Capital expenditures | 5,414 | 1,467 | 285 | 1,887 | 9,053 | ||||||||||||||
Depreciation and amortization | 3,856 | 2,196 | 312 | 389 | 6,753 | ||||||||||||||
Three Months Ended September 30, 2012 | |||||||||||||||||||
Revenues from unaffiliated customers | $ | 124,156 | $ | 100,871 | $ | 20,401 | $ | — | $ | 245,428 | |||||||||
Inter-segment revenues | 638 | 972 | 295 | (1,905 | ) | — | |||||||||||||
Segment operating income (loss) | 36,780 | 32,339 | 6,029 | 232 | 75,380 | ||||||||||||||
Total assets (at end of period) | 289,830 | 247,907 | 28,194 | 72,601 | 638,532 | ||||||||||||||
Capital expenditures | 4,448 | 1,882 | 290 | 2,640 | 9,260 | ||||||||||||||
Depreciation and amortization | 3,557 | 1,874 | 188 | 840 | 6,459 | ||||||||||||||
Nine Months Ended September 30, 2013 | |||||||||||||||||||
Revenues from unaffiliated customers | $ | 386,000 | $ | 337,141 | $ | 74,088 | $ | — | $ | 797,229 | |||||||||
Inter-segment revenues | 2,131 | 2,468 | 1,124 | (5,723 | ) | — | |||||||||||||
Segment operating income (loss) | 107,707 | 113,761 | 23,837 | 197 | 245,502 | ||||||||||||||
Total assets | 320,505 | 261,970 | 37,005 | 37,996 | 657,476 | ||||||||||||||
Capital expenditures | 17,267 | 5,406 | 1,321 | 2,994 | 26,988 | ||||||||||||||
Depreciation and amortization | 11,080 | 5,810 | 692 | 1,160 | 18,742 | ||||||||||||||
Nine Months Ended September 30, 2012 | |||||||||||||||||||
Revenues from unaffiliated customers | $ | 366,724 | $ | 297,151 | $ | 62,750 | $ | — | $ | 726,625 | |||||||||
Inter-segment revenues | 1,934 | 2,055 | 1,099 | (5,088 | ) | — | |||||||||||||
Segment operating income (loss) | 107,271 | 95,434 | 21,057 | (2,350 | ) | 221,412 | |||||||||||||
Total assets | 289,830 | 247,907 | 28,194 | 72,601 | 638,532 | ||||||||||||||
Capital expenditures | 10,594 | 6,150 | 730 | 6,680 | 24,154 | ||||||||||||||
Depreciation and amortization | 10,549 | 4,374 | 530 | 1,966 | 17,419 |
• | Reservoir Description: Encompasses the characterization of petroleum reservoir rock, fluid and gas samples. We provide analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. |
• | Production Enhancement: Includes services and products relating to reservoir well completions, perforations, stimulations and production. We provide integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects. |
• | Reservoir Management: Combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from our clients' reservoirs. |
• | the adoption of legal requirements or taxation relating to climate change that lower the demand for petroleum-based fuels; |
(Unaudited) | Three Months Ended September 30, | % Change | ||||||||||||||
2013 | 2012 | 2013/2012 | ||||||||||||||
REVENUE: | ||||||||||||||||
Services | $ | 194,267 | 71 | % | $ | 174,465 | 71 | % | 11 | % | ||||||
Product sales | 78,896 | 29 | % | 70,963 | 29 | % | 11 | % | ||||||||
Total revenue | 273,163 | 100 | % | 245,428 | 100 | % | 11 | % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Cost of services, exclusive of depreciation expense shown below* | 110,087 | 57 | % | 102,935 | 59 | % | 7 | % | ||||||||
Cost of product sales, exclusive of depreciation expense shown below* | 57,340 | 73 | % | 52,406 | 74 | % | 9 | % | ||||||||
Total cost of services and product sales | 167,427 | 61 | % | 155,341 | 63 | % | 8 | % | ||||||||
General and administrative expenses | 14,346 | 5 | % | 10,504 | 4 | % | 37 | % | ||||||||
Depreciation and amortization | 6,753 | 2 | % | 6,459 | 3 | % | 5 | % | ||||||||
Other (income) expense, net | 41 | 0 | % | (2,256 | ) | (1 | )% | (102 | )% | |||||||
Operating income | 84,596 | 31 | % | 75,380 | 31 | % | 12 | % | ||||||||
Interest expense | 2,302 | 1 | % | 2,160 | 1 | % | 7 | % | ||||||||
Income before income tax expense | 82,294 | 30 | % | 73,220 | 30 | % | 12 | % | ||||||||
Income tax expense | 20,490 | 8 | % | 18,671 | 8 | % | 10 | % | ||||||||
Net income | 61,804 | 23 | % | 54,549 | 22 | % | 13 | % | ||||||||
Net income (loss) attributable to non-controlling interests | (91 | ) | 0 | % | 146 | 0 | % | (162 | )% | |||||||
Net income attributable to Core Laboratories N.V. | $ | 61,895 | 23 | % | $ | 54,403 | 22 | % | 14 | % | ||||||
* Percentage based on applicable revenue rather than total revenue. |
(Unaudited) | Nine Months Ended September 30, | % Change | ||||||||||||||
2013 | 2012 | 2013/2012 | ||||||||||||||
REVENUE: | ||||||||||||||||
Services | $ | 564,424 | 71 | % | $ | 512,883 | 71 | % | 10 | % | ||||||
Product sales | 232,805 | 29 | % | 213,742 | 29 | % | 9 | % | ||||||||
Total revenue | 797,229 | 100 | % | 726,625 | 100 | % | 10 | % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Cost of services, exclusive of depreciation expense shown below* | 329,901 | 58 | % | 304,871 | 59 | % | 8 | % | ||||||||
Cost of product sales, exclusive of depreciation expense shown below* | 164,674 | 71 | % | 155,990 | 73 | % | 6 | % | ||||||||
Total cost of services and product sales | 494,575 | 62 | % | 460,861 | 63 | % | 7 | % | ||||||||
General and administrative expenses | 38,328 | 5 | % | 30,883 | 4 | % | 24 | % | ||||||||
Depreciation and amortization | 18,742 | 2 | % | 17,419 | 2 | % | 8 | % | ||||||||
Other (income), net | 82 | 0 | % | (3,950 | ) | (1 | )% | (102 | )% | |||||||
Operating income | 245,502 | 31 | % | 221,412 | 30 | % | 11 | % | ||||||||
Interest expense | 6,834 | 1 | % | 6,528 | 1 | % | 5 | % | ||||||||
Income before income tax expense | 238,668 | 30 | % | 214,884 | 30 | % | 11 | % | ||||||||
Income tax expense | 60,190 | 8 | % | 53,454 | 7 | % | 13 | % | ||||||||
Net income | 178,478 | 22 | % | 161,430 | 22 | % | 11 | % | ||||||||
Net income (loss) attributable to non-controlling interests | 391 | 0 | % | 160 | 0 | % | 144 | % | ||||||||
Net income attributable to Core Laboratories N.V. | $ | 178,087 | 22 | % | $ | 161,270 | 22 | % | 10 | % | ||||||
* Percentage based on applicable revenue rather than total revenue. |
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||
(Unaudited) | (Unaudited) | ||||||||||||||
Sale of assets | $ | (155 | ) | $ | (70 | ) | $ | (687 | ) | $ | (383 | ) | |||
Results of non-consolidated subsidiaries | 43 | (234 | ) | (142 | ) | (481 | ) | ||||||||
Foreign exchange | 518 | (610 | ) | 3,040 | (280 | ) | |||||||||
Rents and royalties | (156 | ) | (214 | ) | (599 | ) | (809 | ) | |||||||
Insurance recovery | (336 | ) | (1,023 | ) | (882 | ) | (4,490 | ) | |||||||
Legal entity realignment | — | — | — | 1,860 | |||||||||||
NYSE Euronext Amsterdam listing | — | — | — | 923 | |||||||||||
Other, net | 127 | (105 | ) | (648 | ) | (290 | ) | ||||||||
Total other (income) expense, net | $ | 41 | $ | (2,256 | ) | $ | 82 | $ | (3,950 | ) |
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||
(Unaudited) | (Unaudited) | ||||||||||||||
Australian Dollar | $ | 182 | $ | 47 | $ | 391 | $ | 32 | |||||||
British Pound | (430 | ) | (127 | ) | 111 | (68 | ) | ||||||||
Canadian Dollar | (278 | ) | (581 | ) | 690 | (599 | ) | ||||||||
Euro | 266 | (59 | ) | 620 | (66 | ) | |||||||||
Indonesian Rupiah | 320 | 18 | 373 | 158 | |||||||||||
Malaysian Ringgit | 144 | (33 | ) | 332 | 46 | ||||||||||
Mexican Peso | 52 | (179 | ) | 116 | (140 | ) | |||||||||
Russian Ruble | 16 | 164 | (38 | ) | 108 | ||||||||||
Other currencies, net | 246 | 140 | 445 | 249 | |||||||||||
Total (gain) loss | $ | 518 | $ | (610 | ) | $ | 3,040 | $ | (280 | ) |
Three Months Ended September 30, | % Change | ||||||||||
2013 | 2012 | 2013/2012 | |||||||||
Revenue: | (Unaudited) | ||||||||||
Reservoir Description | $ | 131,533 | $ | 124,156 | 6 | % | |||||
Production Enhancement | 119,511 | 100,871 | 18 | % | |||||||
Reservoir Management | 22,119 | 20,401 | 8 | % | |||||||
Consolidated | $ | 273,163 | $ | 245,428 | 11 | % | |||||
Operating income (loss): | |||||||||||
Reservoir Description | $ | 35,938 | $ | 36,780 | (2 | )% | |||||
Production Enhancement | 42,284 | 32,339 | 31 | % | |||||||
Reservoir Management | 6,516 | 6,029 | 8 | % | |||||||
Corporate and Other1 | (142 | ) | 232 | NM | |||||||
Consolidated | $ | 84,596 | $ | 75,380 | 12 | % | |||||
(1) "Corporate and Other" represents those items that are not directly related to a particular segment | |||||||||||
"NM" means not meaningful |
Nine Months Ended September 30, | % Change | ||||||||||
2013 | 2012 | 2013/2012 | |||||||||
Revenue: | (Unaudited) | ||||||||||
Reservoir Description | $ | 386,000 | $ | 366,724 | 5 | % | |||||
Production Enhancement | 337,141 | 297,151 | 13 | % | |||||||
Reservoir Management | 74,088 | 62,750 | 18 | % | |||||||
Consolidated | $ | 797,229 | $ | 726,625 | 10 | % | |||||
Operating income (loss): | |||||||||||
Reservoir Description | $ | 107,707 | $ | 107,271 | 0 | % | |||||
Production Enhancement | 113,761 | 95,434 | 19 | % | |||||||
Reservoir Management | 23,837 | 21,057 | 13 | % | |||||||
Corporate and Other1 | 197 | (2,350 | ) | NM | |||||||
Consolidated | $ | 245,502 | $ | 221,412 | 11 | % | |||||
(1) "Corporate and Other" represents those items that are not directly related to a particular segment | |||||||||||
"NM" means not meaningful |
Nine Months Ended September 30, | % Change | |||||||||
2013 | 2012 | 2013/2012 | ||||||||
Free cash flow calculation: | (Unaudited) | |||||||||
Net cash provided by operating activities | $ | 210,648 | $ | 152,150 | 38 | % | ||||
Less: cash paid for capital expenditures | 26,988 | 24,154 | 12 | % | ||||||
Free cash flow | $ | 183,660 | $ | 127,996 | 43 | % |
Nine Months Ended September 30, | % Change | |||||||||
2013 | 2012 | 2013/2012 | ||||||||
Cash provided by/(used in): | (Unaudited) | |||||||||
Operating activities | $ | 210,648 | $ | 152,150 | 38 | % | ||||
Investing activities | (31,822 | ) | (24,745 | ) | 29 | % | ||||
Financing activities | (175,848 | ) | (132,079 | ) | 33 | % | ||||
Net change in cash and cash equivalents | $ | 2,978 | $ | (4,674 | ) | 164 | % |
Period | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of a Publicly Announced Program | Maximum Number of Shares That May Yet be Purchased Under the Program (3) | |||||||
July 31, 2013 | 123,500 | $ | 151.56 | 123,500 | 2,476,125 | ||||||
August 31, 2013 (1) | 139,325 | 150.14 | 139,325 | 3,375,674 | |||||||
September 30, 2013 (2) | 99,951 | 162.27 | 99,951 | 3,291,382 | |||||||
Total | 362,776 | $ | 153.97 | 362,776 |
Exhibit No. | Exhibit Title | Incorporated by reference from the following documents | |
3.1 | - | Articles of Association of Core Laboratories N.V., as amended in 2012 (including English translation) | Exhibit 3.1 filed on February 19, 2013 with 2012 10-K (File No. 001-14273) |
31.1 | - | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
31.2 | - | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
32.1 | - | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith |
32.2 | - | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith |
101.INS | - | XBRL Instance Document | Filed herewith |
101.SCH | - | XBRL Schema Document | Filed herewith |
101.CAL | - | XBRL Calculation Linkbase Document | Filed herewith |
101.LAB | - | XBRL Label Linkbase Document | Filed herewith |
101.PRE | - | XBRL Presentation Linkbase Document | Filed herewith |
101.DEF | - | XBRL Definition Linkbase Document | Filed herewith |
CORE LABORATORIES N.V. | |||
Date: | October 18, 2013 | By: | /s/ Richard L. Bergmark |
Richard L. Bergmark | |||
Chief Financial Officer | |||
(Duly Authorized Officer and | |||
Principal Financial Officer) |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting. |
Date: | October 18, 2013 | By: | /s/ David M. Demshur |
David M. Demshur | |||
Chief Executive Officer |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting. |
Date: | October 18, 2013 | By: | /s/ Richard L. Bergmark |
Richard L. Bergmark | |||
Chief Financial Officer |
Date: | October 18, 2013 | /s/ David M. Demshur |
Name: David M. Demshur | ||
Title: Chief Executive Officer |
Date: | October 18, 2013 | /s/ Richard L. Bergmark |
Name: Richard L. Bergmark | ||
Title: Chief Financial Officer |
7!E("],:6YK("]296-T(%LU,C@@-3$U+C`P.#(P
M,S$R-2`U,S,@-3(T+C%=("]";W)D97(@6S`@,"`P72`O2"`O22`O1&5S="!;
M,3$@,"!2("]865H@,"`W.3(N,#`@;G5L;%T^/CP\+U1Y<&4@+T%N;F]T("]3
M=6)T>7!E("],:6YK("]296-T(%LQ,S0@-#@U+C`P.#(P,S$R-2`T.#@N-#,X
M-# 7!E("],:6YK("]296-T
M(%LU,C@@-#(U+C`P.#(P,S$R-2`U,S,@-#,T+C%=("]";W)D97(@6S`@,"`P
M72`O2"`O22`O1&5S="!;,34@,"!2("]865H@,"`W.3(N,#`@;G5L;%T^/CP\
M+U1Y<&4@+T%N;F]T("]3=6)T>7!E("],:6YK("]296-T(%LQ,S0@,SDU+C`P
M.#(P,S$R-2`S.3DN-S@Q,C4@-#`T+C%=("]";W)D97(@6S`@,"`P72`O2"`O
M22`O1&5S="!;,3<@,"!2("]865H@,"`W.3(N,#`@;G5L;%T^/CP\+U1Y<&4@
M+T%N;F]T("]3=6)T>7!E("],:6YK("]296-T(%LU,C@@,SDU+C`P.#(P,S$R
M-2`U,S,@-#`T+C%=("]";W)D97(@6S`@,"`P72`O2"`O22`O1&5S="!;,3<@
M,"!2("]865H@,"`W.3(N,#`@;G5L;%T^/CP\+U1Y<&4@+T%N;F]T("]3=6)T
M>7!E("],:6YK("]296-T(%LW-BXS(#,V-2XP,#@R,#,Q,C4@,3`T+C8R-3$Y
M-3,Q,C4@,S7!E("]!;FYO="`O4W5B='EP92`O3&EN:R`O4F5C="!;-3(U
M+C4@,30Q+C`P.#(P,S$R-3`P,#`R(#4S-2XU(#$U,"XQ,#`P,#`P,#`P,#`P
M,ET@+T)O